Skip to content

Levothyroxine treatment during Ramadan

Levothyroxine treatment during Ramadan: a prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN54141719
Enrollment
150
Registered
2021-02-17
Start date
2019-04-23
Completion date
Unknown
Last updated
2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothyroidism Nutritional, Metabolic, Endocrine Hypothyroidism, unspecified

Interventions

In a randomized prospective design, hypothyroid patients taking levothyroxine are randomized to take levothyroxine at one of the following three times during Ramadan: (group 1) at dusk 30 minutes befo

Sponsors

Cleveland Clinic Abu Dhabi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older 2. Hypothyroidism treated with levothyroxine for over 6 months 3. Planning to fast during the month of Ramadan 3. Ability to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years 2. Inability to provide an informed consent

Design outcomes

Primary

MeasureTime frame
Thyroid function tests (plasma TSH and free-T4) measured on the Roche e601 immunoassay analyzer using the electrochemiluminescence immunoassay (ECLIA) sandwich principle for TSH and the ECLIA competition principle for free-T4, within 3 months before Ramadan and repeated within 6 weeks post-Ramadan

Secondary

MeasureTime frame
1. The impact of age and gender on the primary outcome measure, change in thyroid function tests (see above) from pre-to post-Ramadan 2. Patient compliance and satisfaction with the assigned randomized treatment assessed with a telephone call to each patient at the end of the study

Countries

United Arab Emirates

Contacts

Public ContactSamer El-Kaissi
elkaiss@clevelandclinicabudhabi.ae+971 (0)2 501 9000

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026